Actively Recruiting
Evaluating the Safety and Effects of HSK31679 in Adults With Metabolic Dysfunction-Associated Steatohepatitis MASH in a Randomized, Placebo-Controlled Study
Led by Haisco Pharmaceutical Group Co., Ltd. · Updated on 2026-09-23
886
Participants Needed
1
Research Sites
182 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of the drug HSK31679 in adults with metabolic dysfunction-associated steatohepatitis MASH, a serious liver condition. This phase 3, randomized, double-blind, placebo-controlled study aims to compare HSK31679 to a placebo to better understand its impact on MASH and liver fibrosis. The study consists of two parts based on specific liver biopsy or non-invasive test criteria to assess both the drugs effect and safety in improving liver function. Participants will receive either an oral tablet of HSK31679 once daily or a matching placebo. The first part focuses on evaluating how HSK31679 affects MASH and liver fibrosis, while the second part aims to determine its safety in improving liver health. Treatments are assigned randomly, and neither participants nor researchers know who receives the drug or placebo to maintain impartial results. During the study, participants will undergo screening including liver biopsies or non-invasive tests to confirm eligibility. Researchers will monitor liver health and fibrosis stages over time, with key measurements at 52 weeks and up to 4.5 years for disease progression. Safety and tolerability are closely observed, ensuring participant health throughout the study period, which can last several years from enrollment to completion.
CONDITIONS
Brief Title
A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH
Research Team
F
fangqiong li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here